DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 12,268,547. Although the claims at issue are not identical, they are not patentably distinct from each other because both application and patent claim a method for estimating quantitative blood flow using three dimensional parametric imaging data.
Application No. 19/172012
U. S. Patent No. 12,268,547
1. A method for estimating quantitative blood flow using three dimensional parametric imaging data, comprising the steps of: a. pre-processing of images comprises:(i) reconstructing dynamic perfusion imaging data,(ii) isolating value at voxel (i,j,k) for each time point ti, where i is from 1 to N,(iii) extracting blood input function from a region of interest (ROI), and(iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/K2), to stabilize and improve estimation of K1, K2, total blood volume (TBV), subsequent blood flow measures, and data normalization; b. assessing the individual signals pre-processed in step (a) to generate K1 and TBV parametric maps using artificial neural network; and c. post-processing of K1, K2 and TBV parametric maps to estimate the blood flow and flow reserve map.
2. The method according to claim 1, wherein the image reconstruction of arrays is a dynamic series comprising the 3D tomographic volumes from PET reconstruction for the number of time steps, ti where i is from 1 to N.
3. The method according to claim 1, wherein a region of interest (ROI) can be manual and/or automatic procedures.
4. The method according to claim 1, wherein the data normalization obtained by dividing with the maximum of the blood input function.
5. The method according to claim 1, wherein the data normalization for blood input function with the value is from 0 to 1.
8. The method according to claim 1, wherein the artificial neural networks are selected from the group consisting of multi-layer perceptron (MLP), artificial neural network (ANN), convolutional neural network (CNN), recurrent neural network (RNN), long short- term memory recurrent neural network (LSTM-RNN), gated recurrent unit (GRU) network, generative adversarial networks (GANs), deep machine learning and/or combinations thereof.
9. The method according to claim 1, wherein to estimate distribution volume (DV) artificial neural network enter in multiple layers and wherein the multiple layers selected from the group consisting of the initial layer of the network, at an intermediate layer, at the penultimate layer, or combinations thereof.
10. The method according to claim 9, wherein the model predicts a K2 (washout rate) value.
11. The method according to claim 1, wherein estimating K1, K2 and total blood volume (TBV) by performing on a voxel-wise basis using 1D signal CNN-LSTM to produce more accurate blood flow estimations.
12. The method according to claim 1, wherein the images are characterized by administering imaging agent or radionuclide selected from the group consisting of Rb-82, 0-15, N-13, Cu-62-PTSM, 99m-Tc-Sestamibi, Tl-201, and/or combinations thereof.
13. The method according to claim 1, wherein the images are characterized by administering Rb-82 in rest and stress PET perfusion imaging to highlights small regional flow defects.
14. The method according to claim 12, wherein the imaging agent or radionuclide is administered by automated generation and infusion system and/or intravenous administration of radiopharmaceuticals produced by fission, neutron activation, cyclotron and/or generator.
15. The method according to claim 14, wherein automated radioisotope generation and infusion system comprises Rb-82 elution system.
16. The method according to claim 1, wherein the images obtained fit to one-tissue- compartment model by predicting the value of the ratio of blood flow stress and blood flow rest to determine flow reserve and wherein performing an assessment of the obtained images to diagnose disease state using multi-layer perceptron (MLP), artificial neural network (ANN), convolutional neural network (CNN), recurrent neural network (RNN), long short-term memory recurrent neural network (LSTM-RNN), gated recurrent unit (GRU) network, generative adversarial networks (GANs), deep machine learning and/or combinations thereof.
17. The method according to claim 1, wherein the imaging comprises positron emission tomography (PET) imaging, dynamic positron emission tomography, single-photon emission computerized tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), and/or combinations thereof.
18. An image processing method to assess quantitative blood flow and flow reserve, comprising the steps of:a. pre-processing of images obtained by using radiotracer, comprising the steps of:(i) reconstructing dynamic cine 3D tomographic perfusion imaging data, (ii) isolating value at voxel (i,j,k) for each time point ti, where i is from 1 to N, (iii) extracting blood input function from a region of interest (ROI), (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/K2) to stabilize and improve estimation of K1, K2, total blood volume (TBV), subsequent blood flow measures, and data normalization; b. applying the time series at voxel (i,j,k) and blood input function to artificial intelligence network simultaneously to predict uptake K1, K2 and TBV with an average R2 values, wherein the average R2 values are in between 0.9 to 1; c. post-processing of K1, K2 and TBV parametric maps comprises:(i) partial volume correction,(ii) extraction fraction to estimate blood flow at rest and stress; and d. post-processing of rest and stress blood flow to estimate flow reserve map and/or flow reserve map; wherein by analyzing myocardial flow reserve (MFR) map and/or coronary flow reserve (CFR) map, recommending diseases.
19. An image processing method to assess quantitative blood flow, comprising the steps of: a. pre-processing of images comprises:(i) reconstructing dynamic cine 3D tomographic perfusion imaging data,(ii) isolating value at voxel (i,j,k) for each time point ti, where i is from 1 to N,(iii) extracting blood input function from a region of interest (ROI), (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/K2) to stabilize and improve estimation of K1, K2, total blood volume (TBV), subsequent blood flow measures, and data normalization; b. applying the time series at voxel (i,j,k) and blood input function to artificial intelligence network simultaneously to predict uptake K1 and TBV with an average R2 values, wherein the average R2 values are in between 0.9 to 1; c. post-processing of K1 and TBV parametric maps comprises:(i) partial volume correction,(ii) extraction fraction to estimate blood flow at rest and stress; and d. post-processing of rest and stress blood flow to estimate flow reserve map; wherein the artificial neural networks are selected from the group consisting of multi- layer perceptron (MLP), artificial neural network (ANN), convolutional neural network (CNN) and/or 1D convolutional neural network (1D-CNN), recurrent neural network (RNN), long short-term memory recurrent neural network (LSTM-RNN), gated recurrent unit (GRU) network, generative adversarial networks (GANs), deep machine learning and/or combinations thereof, wherein the blood input function is extracted from heart or/and liver or/and kidney or combinations thereof.
1. An image processing method to assess quantitative myocardial blood flow and/or myocardial flow reserve, comprising the steps of: a. pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) isolating value at voxel (i,j,k) for each time point t.sub.i where i is from 1 to N, (iii) optionally, denoising to improve the quality of image, (iv) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity or other arterial blood region of interest (ROI), (v) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K.sub.1/k.sub.2), to stabilize and improve estimation of K.sub.1, k.sub.2 and total blood volume (TBV) and subsequent myocardial blood flow measures, and (vi) data normalization by dividing by the maximum of the blood input function; b. assessing the individual signals pre-processed in step (a) in order to generate K.sub.1 and TBV parametric maps using artificial neural network; c. post-processing of K.sub.1, k.sub.2 and TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocardial flow reserve (MFR) map and/or coronary flow reserve (CFR) map.
2. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the image reconstruction of arrays is a dynamic series comprising the 3D tomographic volumes from PET reconstruction for the number of time steps, t.sub.i where i is from 1 to N.
3. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein a region of interest (ROI) can be manual and/or automatic procedures.
4. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the data normalization by dividing by the maximum of the blood input function.
5. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the data normalization for blood input function with the value is from 0 to 1.
8. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the artificial neural networks are selected from the group consisting of multi-layer perceptron (MLP), artificial neural network (ANN), convolutional neural network (CNN), recurrent neural network (RNN), long short-term memory recurrent neural network (LSTM-RNN), gated recurrent unit (GRU) network, Generative adversarial networks (GANs), deep machine learning and/or combinations thereof.
9. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein to estimate distribution volume (DV) artificial neural network enter in multiple layers and wherein the multiple layers can be selected from the group consisting of the initial layer of the network, at an intermediate layer, at the penultimate layer, or combinations thereof.
10. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 9, wherein the model predicts a k.sub.2 (washout rate) value.
11. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein estimating K.sub.1, k.sub.2 and total blood volume (TBV) by performing on a voxel-wise basis using 1D signal CNN-LSTM to produce more accurate myocardial blood flow (MBF) estimations.
12. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the images are characterized by administering Rb-82, O-15, N-13, Cu-62-PTSM, 99m-Tc-Sestamibi, Tl-201, and/or combinations thereof.
13. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the images are characterized by administering Rb-82 in rest and stress PET perfusion imaging to highlights small regional flow defects.
14. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the imaging agent or radionuclide is administered by automated generation and infusion system and/or intravenous administration of radiopharmaceuticals produced by fission, neutron activation, cyclotron and/or generator.
15. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein automated radioisotope generation and infusion system comprises Rb-82 elution system.
16. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the images obtained fit to one-tissue-compartment model by predicting the value of the ratio of myocardial blood flow stress and myocardial blood flow rest to determine myocardial flow reserve and/or coronary flow reserve and wherein performing an assessment of the obtained images to diagnose disease state using multi-layer perceptron (MLP), artificial neural network (ANN), convolutional neural network (CNN), recurrent neural network (RNN), long short-term memory recurrent neural network (LSTM-RNN), gated recurrent unit (GRU) network, Generative adversarial networks (GANs), deep machine learning and/or combinations thereof.
17. The image processing method to assess quantitative myocardial blood flow and myocardial flow reserve according to claim 1, wherein the imaging comprises positron emission tomography (PET) imaging, dynamic positron emission tomography, single-photon emission computerized tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), and/or combinations thereof.
18. A myocardial image processing method to assess quantitative myocardial blood flow and myocardial flow reserve, comprising the steps of: a. pre-processing of images obtained by using Rubidium-82 radiotracer, comprising the step of: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) isolating value at voxel (i,j,k) for each time point t.sub.i where i is from 1 to N, (iii) optionally, denoising to improve the quality of images, (iv) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity or other arterial blood region of interest (ROI), (v) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K.sub.1/k.sub.2) to stabilize and improve estimation of K.sub.1, k.sub.2 and total blood volume (TBV) and subsequent myocardial blood flow measures, (vi) data normalization by dividing by the maximum of the blood input function; b. applying the time series at voxel (i,j,k) and blood input function to artificial intelligence network simultaneously to predict uptake K.sub.1, k.sub.2 and TBV, c. post-processing of K.sub.1, k.sub.2 and TBV parametric maps comprises: (i) partial volume correction, (ii) extraction fraction to estimate myocardial blood flow (MBF) at rest and stress; and d. post-processing of rest and stress myocardial blood flow to estimate myocardial flow reserve (MFR) map and/or coronary flow reserve (CFR) map; wherein by analyzing the MBF and/or MFR map, recommending coronary diseases.
19. An image processing method to assess quantitative myocardial blood flow and myocardial flow reserve, comprising the steps of: a. pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) isolating value at voxel (i,j,k) for each time point t.sub.i where i is from 1 to N, (iii) optionally, denoising to improve the quality of image, (iv) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity or other arterial blood region of interest (ROI), (v) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K.sub.1/k.sub.2) to stabilize and improve estimation of K.sub.1, k.sub.2 and total blood volume (TBV) and subsequent myocardial blood flow measures, and (vi) data normalization by dividing by the maximum of the blood input function; b. applying the time series at voxel (i,j,k) and blood input function to artificial intelligence network simultaneously to predict uptake K.sub.1 and TBV, wherein the average R.sup.2 values are in between 0.9 to 1: c. post-processing of K.sub.1 and TBV parametric maps comprises: (i) partial volume correction, (ii) extraction fraction to estimate myocardial blood flow (MBF) at rest and stress; and d. post-processing of rest and stress myocardial blood flow to estimate myocardial flow reserve (MFR) map and/or coronary flow reserve (CFR) map; wherein the artificial neural networks are selected from the group consisting of, multi-layer perceptron (MLP), artificial neural network (ANN), convolutional neural network (CNN) and/or 1D convolutional neural network (1D-CNN), recurrent neural network (RNN), long short-term memory recurrent neural network (LSTM-RNN), gated recurrent unit (GRU) network, generative adversarial networks (GANs), deep machine learning and/or combinations thereof.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SANJAY CATTUNGAL whose telephone number is (571)272-1306. The examiner can normally be reached M-F 9-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Keith Raymond can be reached at 571-270-1790. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SANJAY CATTUNGAL/Primary Examiner, Art Unit 3798
Prosecution Insights